Related Experiment Video
Updated: Jul 3, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular
Mutlu Dogan1, Ahmet Demirkazik
1Department of Medical Oncology, Cebeci Hospital, Ankara University, Turkey.
Abstract:
Venous thromboembolism (VTE) is a well-recognized problem in malignancy. Patients with cancer who have VTE have a worse prognosis than other patients with cancer. Hypercoagulability in patients with cancer is related to malignancy itself and its treatment. These patients have multiple risk factors for thromboembolism, such as being immobilized, having central venous catheters, and receiving chemoradiation therapy. Cancer procoagulant, tissue factor, factor VIII, and thrombin have important roles in causing cancer-associated thromboembolism. Tumors require neovascularization for delivering oxygen and other nutrients. Therefore, angiogenesis facilitates tumor growth, invasion, and metastasis. New blood vessels formed by angiogenesis are thrombogenic. Hypercoagulability and tumor growth are closely related. Vascular endothelial growth factor (VEGF) is a proangiogenic factor that may also cause VTE in patients with cancer. The relationship between cancer, angiogenesis, VEGF, and thrombosis is reviewed herein. Studies are ongoing to enhance our understanding of this complex interaction.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
